| Literature DB >> 27736905 |
Sara K Custer1, Timra D Gilson1, Hongxia Li1, A Gary Todd1, Jacob W Astroski1, Hai Lin2, Yunlong Liu2, Elliot J Androphy1.
Abstract
Spinal muscular atrophy (SMA) is an intractable neurodegenerative disease afflicting 1 in 6-10,000 live births. One of the key functions of the SMN protein is regulation of spliceosome assembly. Reduced levels of the SMN protein that are observed in SMA have been shown to result in aberrant mRNA splicing. SMN-dependent mis-spliced transcripts in motor neurons may cause stresses that are particularly harmful and may serve as potential targets for the treatment of motor neuron disease or as biomarkers in the SMA patient population. We performed deep RNA sequencing using motor neuron-like NSC-34 cells to screen for SMN-dependent mRNA processing changes that occur following acute depletion of SMN. We identified SMN-dependent splicing changes, including an intron retention event that results in the production of a truncated Rit1 transcript. This intron-retained transcript is stable and is mis-spliced in spinal cord from symptomatic SMA mice. Constitutively active Rit1 ameliorated the neurite outgrowth defect in SMN depleted NSC-34 cells, while expression of the truncated protein product of the mis-spliced Rit1 transcript inhibited neurite extension. These results reveal new insights into the biological consequence of SMN-dependent splicing in motor neuron-like cells.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27736905 PMCID: PMC5063418 DOI: 10.1371/journal.pone.0163954
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Fig 1SMN depletion leads to defective U-snRNP biogenesis.
A) Doxycycline treatment (2μg/ml) for 72 hrs reduced SMN protein levels by ~70% in NSC-34-4#56, which contain both the RTta and the SMN shRNA but not NSC-34 cell clone 4 which expresses only the RTta. B) Quantification of three separate western blot of SMN protein level after doxycycline treatment in NSC-34-4#56. C) Quantitative RT-PCR shows mRNA levels of UsnRNPs after doxycycline-induced SMN depletion compared to untreated cells (dashed line). All samples were compared to levels of the 18S subunit. *–p<0.01. One-way ANOVA followed by post-hoc t-test.
SMN-dependent exon skipping events ranked by percent inclusion.
| Gene Name | Δ-psi | Baye's factor | Event |
|---|---|---|---|
| Tomm20l | -0.83 | 62.49 | chr12:72218513:72218594:+@chr12:72222851:72222993:+@chr12:72224036:72224899:+ |
| Ppp3cb | -0.73 | 10466467.31 | chr14:21327846:21327943:-@chr14:21322469:21322498:-@chr14:21319252:21320884:- |
| Prmt1 | -0.67 | 35020.18 | chr7:52241653:52241938:-@chr7:52239450:52239503:-@chr7:52238856:52238957:- |
| Ppp2r3a | -0.65 | 1082.85 | chr9:101027353:101027459:-@chr9:101019508:101019634:-@chr9:101007322:101010299:- |
| Rufy3 | -0.6 | 7.69 | chr5:89012085:89013342:+@chr5:89027461:89027514:+@chr5:89043966:89045604:+ |
| Zbtb46 | -0.6 | 7.21 | chr2:181193961:181194132:-@chr2:181181407:181181589:-@chr2:181153313:181159093:- |
| Gyg | -0.59 | 5.2 | chr3:20025144:20025363:-@chr3:20023008:20023058:-@chr3:20021967:20022750:- |
| Trmt5 | -0.58 | 16869052884 | chr12:74387671:74387976:-@chr12:74386891:74386962:-@chr12:74385198:74386262:- |
| Camkk2 | -0.56 | 8.86 | chr5:123187442:123187542:-@chr5:123186997:123187039:-@chr5:123181178:123184254:- |
| Pik3c2a | -0.55 | 10849865.75 | chr7:123586818:123587034:-@chr7:123586105:123586192:-@chr7:123560967:123562095:- |
| Samhd1 | -0.55 | 2935.02 | chr2:156927457:156927594:-@chr2:156927057:156927179:-@chr2:156923265:156925239:- |
| Mettl9 | -0.54 | 50.5 | chr7:128200729:128200913:+@chr7:128216322:128216324:+@chr7:128219647:128219888:+ |
| Slc44a2 | -0.54 | 17.84 | chr9:21156911:21156995:+@chr9:21157445:21157572:+@chr9:21158126:21159473:+ |
| Fam35a | -0.52 | 8022922821 | chr14:35122226:35122651:-@chr14:35082657:35082722:-@chr14:35079315:35082138:- |
| Nop58 | -0.51 | 53505.63 | chr1:59741784:59742070:+@chr1:59745414:59745463:+@chr1:59747330:59747833:+ |
| Immt | -0.5 | 322.38 | chr6:71802268:71802861:+@chr6:71803167:71803262:+@chr6:71806906:71807042:+ |
| Mettl7a1 | -0.5 | 11.45 | chr15:100135192:100135775:+@chr15:100140255:100140335:+@chr15:100143425:100144797:+ |
| Ube2l3 | -0.5 | 6.9 | chr16:17176505:17176600:-@chr16:17171856:17171954:-@chr16:17157390:17160269:- |
| Tmbim6 | -0.49 | 303.79 | chr15:99223310:99223471:+@chr15:99224126:99224161:+@chr15:99232011:99232094:+ |
| Lrrc14 | -0.48 | 7.69 | chr15:76541068:76541266:+@chr15:76541394:76541513:+@chr15:76543297:76544415:+ |
| Rap2c | -0.46 | 1460032.12 | chrX:48368148:48368460:-@chrX:48361469:48361662:-@chrX:48357083:48359927:- |
| Nxt1 | -0.46 | 8.36 | chr2:148498337:148498571:+@chr2:148500200:148500334:+@chr2:148501018:148501771:+ |
| Wdyhv1 | -0.46 | 7.44 | chr15:57982161:57982211:+@chr15:57985135:57985259:+@chr15:57989457:57990220:+ |
| Myef2 | -0.45 | 2743.52 | chr2:124913413:124914747:-@chr2:124913279:124913325:-@chr2:124910364:124912452:- |
| Krit1 | -0.45 | 22.35 | chr5:3822087:3823785:+@chr5:3827628:3827761:+@chr5:3830606:3830772:+ |
| Elk3 | -0.44 | 197.37 | chr10:92747514:92747722:-@chr10:92727625:92728425:-@chr10:92717434:92717556:- |
| Ptar1 | -0.44 | 25.67 | chr19:23783244:23783457:+@chr19:23792303:23792592:+@chr19:23794548:23795619:+ |
| Gpatch2 | -0.44 | 7.76 | chr1:189049382:189050098:+@chr1:189053478:189053539:+@chr1:189054663:189054724:+ |
| Maged1 | -0.44 | 5.27 | chrX:91787231:91787417:-@chrX:91786590:91786663:-@chrX:91785194:91785886:- |
| Dnajc5 | -0.43 | 7.73 | chr2:181283375:181283546:+@chr2:181283631:181283705:+@chr2:181283978:181289837:+ |
| Znrf1 | -0.42 | 6.47 | chr8:114059994:114061464:+@chr8:114130647:114130748:+@chr8:114133193:114133288:+ |
| Ywhab | -0.42 | 5.98 | chr2:163837338:163837640:+@chr2:163837732:163837734:+@chr2:163839745:163839865:+ |
| Rcor3 | -0.41 | 8.64 | chr1:193940150:193940227:-@chr1:193925633:193925748:-@chr1:193922425:193925036:- |
| Rhot1 | -0.4 | 5.13 | chr11:80068162:80068364:+@chr11:80071016:80071138:+@chr11:80079244:80081409:+ |
| Hnrnpd | -0.38 | 324.99 | chr5:100391534:100391631:-@chr5:100391117:100391223:-@chr5:100384954:100390352:- |
| Orai3 | -0.38 | 93.11 | chr7:134913328:134913730:+@chr7:134914248:134914392:+@chr7:134917071:134918668:+ |
| Rps14 | -0.37 | 2631505.51 | chr18:60934164:60934340:+@chr18:60936055:60936205:+@chr18:60936584:60937062:+ |
| Magi1 | -0.37 | 11.97 | chr6:93632946:93633084:-@chr6:93630783:93630871:-@chr6:93625447:93628996:- |
| Clstn1 | -0.35 | 22.39 | chr4:149012342:149012504:+@chr4:149015767:149015823:+@chr4:149017304:149017461:+ |
| Stx11 | -0.32 | 7.07 | chr10:12683806:12684291:-@chr10:12663958:12664092:-@chr10:12659787:12661787:- |
| Josd2 | -0.31 | 7.77 | chr7:51723021:51723560:+@chr7:51723676:51723787:+@chr7:51724177:51725907:+ |
| Aldoa | -0.29 | 49.79 | chr7:133942559:133942769:-@chr7:133941488:133941492:-@chr7:133940851:133941290:- |
| Eif4h | -0.28 | 6.75 | chr5:135101236:135101332:-@chr5:135100311:135100370:-@chr5:135097819:135097956:- |
| Pcmt1 | -0.27 | 29.77 | chr10:7368849:7368953:-@chr10:7368265:7368458:-@chr10:7367068:7367419:- |
| Hnrnpa2b1 | -0.25 | 36.75 | chr6:51419670:51420485:-@chr6:51417390:51417425:-@chr6:51417184:51417294:- |
| Hnrnpa2b1 | -0.22 | 294.78 | chr6:51416302:51416403:-@chr6:51414088:51414102:-@chr6:51411919:51413492:- |
| Stard4 | -0.21 | 8.1 | chr18:33365774:33365900:-@chr18:33364875:33364979:-@chr18:33358792:33363469:- |
SMN-dependent intron retention events ranked by percent inclusion.
| Gene Name | Δ-psi | Baye's factor | Event |
|---|---|---|---|
| Vps33b | -0.55 | 242.16 | chr7:87436001:87436176:+@chr7:87436221:87436465:+ |
| Ing4 | -0.5 | 29.19 | chr6:124997500:124997958:+@chr6:124998194:124998255:+ |
| Ibtk | -0.46 | 5.49 | chr9:85611158:85611259:-@chr9:85608906:85609023:- |
| Rit1 | -0.37 | 21035.04 | chr3:88529917:88529990:+@chr3:88530202:88530393:+ |
| Srsf1 | -0.27 | 2668051.53 | chr11:87862545:87862717:+@chr11:87862914:87867259:+ |
| Cenpt | -0.25 | 123.29 | chr8:108373733:108373823:-@chr8:108373526:108373613:- |
| Atg9a | -0.19 | 5.19 | chr1:75179166:75179311:-@chr1:75177439:75178505:- |
| Ptbp1 | -0.15 | 11.61 | chr10:79322097:79322267:+@chr10:79322347:79322457:+ |
| Psmb6 | -0.07 | 9.27 | chr11:70339387:70339454:+@chr11:70339796:70339927:+ |
RNA-seq workflow and quality control.
| Condition | total RNA control | total RNA SMN knockdown | ||||
|---|---|---|---|---|---|---|
| Sample | experiment 1 | experiment 2 | experiment 3 | experiment 1 | experiment 2 | experiment 3 |
| Total reads | 30,113,572 | 30,088,415 | 26,659,894 | 29,684,299 | 39,127,193 | 33,014,903 |
| Passed QC | 25,254,611 | 23,761,419 | 22,115,822 | 24,304,285 | 32,199,505 | 25,683,819 |
| Passed rRNA filter | 13,265,153 | 19,533,367 | 20,479,028 | 1,384,802 | 9,273,930 | 10,518,125 |
| (rRNA filter) | 11,989,458 | 4,228,052 | 1,636,794 | 22,919,483 | 22,925,575 | 15,165,694 |
| Mapped | 10,043,543 | 13,298,811 | 15,517,242 | 1,033,316 | 6,849,638 | 7,303,336 |
| Unmapped | 3,221,610 | 6,234,556 | 4,961,786 | 351,486 | 2,424,292 | 3,214,789 |
Fig 2SMN depletion results in alternative exon splicing.
A) RT-PCR documented alternative splicing events following SMN depletion for three group 1 and one group 2 transcripts. The histograms show the posterior distributions over PSI estimated by MISO in control or SMN-depleted samples conditions. The red lines depict the posterior mean and the dotted grey lines indicate 95% confidence intervals (also shown in parenthesis). B) Quantification of RT-PCR band intensity from 3 biological replicates showed increased alternative splicing after SMN depletion but not after doxycycline treatment of NSC-34-4. C) Gene Ontology results for exon skipping events and exon retention events induced by SMN depletion. *–p<0.01. One-way ANOVA followed by post-hoc t-test.
Fig 3SMN depletion results in alternative intron usage.
A) RT-PCR demonstrated increased intron retention events in doxycycline treated NSC-34-4#56, but not NSC-34-4. The histograms show the posterior distributions over PSI estimated by MISO in control or SMN-depleted samples conditions. The red lines depict the posterior mean and the dotted grey lines indicate 95% confidence intervals (also shown in parenthesis). B) Quantification of RT-PCR band intensity from 3 biological replicates shows increased intron retention after SMN depletion, but not after doxycycline treatment of NSC-34-4. *–p<0.01. One-way ANOVA followed by post-hoc t-test.
Fig 4Tmem41b is alternatively spliced in SMN-depleted NSC-34 cells.
A) Endpoint RT-PCR shows no alternative splicing of Tmem41b or retention of the U12 dependent intron 3 in either parental cell line NSC-34 #4 or the doxycycline-inducible SMN knockdown line NSC-34 #4–56 following 72 hours of doxycycline. B) Quantitative RT-PCR shows a significant 20% increase in U12 intron retention and alternative splicing in Tmem41b after doxycycline-induced SMN depletion but no decrease in total Tmem41b levels. *–p<0.05 by Student’s t-test.
Fig 5RNA binding protein motifs at sites of alternative exon splicing.
A) The upstream and down-stream intronic regions for each alternatively spliced exon were interrogated for the presence of pentameric RNA binding protein motifs. No significant RBP recognition sites were identified within exons or in the up- or downstream exon. B) The total number of recognition motifs for each RNA binding protein is displayed. Only hnRNP-L/LL and RMP4 binding motifs were present at both retained and skipped exons.
Fig 6Aberrant splicing is rescued by reintroduction of human SMN.
A) NSC-34-4#56 cells were transfected with HA-tagged human SMN. Western blotting with antibodies against SMN (MANSMA1) showed that doxycycline reduced the levels of mouse SMN but the HA-hSMN was unaffected and brought levels of SMN protein within normal range after 72 hours in doxycycline. B) RT-PCR on SMN-depleted and HA-hSMN expressing cultures shows rescue of three major splicing change categories. C-D) Quantitative real-time PCR (qRT-PCR) demonstrated that the aberrant splice products from exon skipping/retention (6C) or intron retention (6D) were only present after doxycycline-induced SMN depletion, and normalized with expression of human SMN. Schematic shows the location of primers for qRT-PCR quantification of alternative splice products.
Fig 7Retained introns are not targets of non-sense mediated decay.
A) Quantitative RT-PCR measures intron-retained transcripts after treatment with cycloheximide. mRNA levels were compared to vehicle treated (EtOH) cultures using 5S rna as the internal reference by the ΔΔCT method. Arc, a validated NMD target increased while only Rit1 showed any significant increase, indicating that these transcripts are not targets of NMD. B) Quantitative RT-PCR compared total transcript levels in SMN-depleted cultures to control cultures using 5S rna as the internal reference by the ΔΔCT method. Cenpt was slightly decreased after SMN depletion, but neither Srsf1 nor Rit1 transcript are decreased overall after SMN depletion. (Asterisk–p<0.05 by Student’s t-test).
Fig 8Alternative splicing in a mouse model of SMA.
A) Kaplan-Meier analysis shows a significantly decreased lifespan in SMA mice compared to heterozygous (Het) littermates (p<0.01 n = 50). B) SMA mice fail to gain and maintain weight compared to the Het siblings (p<0.01 by two-way ANOVA). C) At postnatal day 9, SMA spinal cords show increased levels of exon-skipped transcripts and intron-retained transcripts compared to Het spinal cords (p<0.05 by Student’s t-test).
Fig 9Alternatively spliced CnAβ and Srsf1 do not impact normal biology.
A) Immunofluorescent detection of NFATc localization (green) in NSC-34 4#56 cultures showed that SMN knockdown did not increase nuclear localization of NFATc. Nuclei were visualized with DAPI (blue). B) Quantification of NFATc localization in three separate experiments showed no significant effect of SMN depletion. C) Schematic of Srsf1 protein domains. RRM: RNA Recognition Motif, RS: Arginine/Serine rich region, FL: full length, Iso3: naturally alternatively spliced dominant negative product, TM: alternatively spliced truncation mutant induced upon SMN knockdown. D) FL and TM Srsf1 expression. FLAG Western blot of FLAG-Srsf1 constructs expressed in NSC-34-4#56 cells. E) Srsf1 expression did not affect SMN splicing. RNA was harvested from NSC-34-4#56 cells transfected with FLAG-Srsf1 FL/TM and SMN1/2 minigene plasmids. SMN1 and SMN2 were PCR amplified and run on an agarose gel. Addition of 100μM Na3VO4 shows that the SMN2 minigene is functional, increasing the amount of exon 7 included transcript. F) Endogenous Srsf1-TM was not detectable upon SMN knockdown. Western blotting with N-terminal Srsf1 antibody of control and DOX treated NSC-34-4#56 cells detected the full length Srsf1 protein, but not the predicted Srsf1-TM (arrow).
Fig 10Alternatively spliced Rit1 decreases neurite length.
A) Schematic of Rit1 protein domains. Protein sequence shown of minimal consensus G1-G5 domains of Ras family members on top followed by the mouse Rit1 specific sequence and corresponding amino acid position. SwI: Switch I, SwII: Switch II domains, FL: Full length, TM: truncation mutant. B) Representative levels of SMN for NSC34-4#56 cells used in panels D and E upon dox-induced knockdown. C) Western blot expression of FLAG tagged dominant negative Rit S35N, constitutively active Rit Q79L, full length Rit (FL), and alternatively spliced Rit truncation mutant (TM). D) Neurite extension assay. NSC34-4#56 cells were dox treated for 3 days followed by transfection of FLAG-Rit /GFP for 3 days. Cells were fixed and tubulin stained to allow neurite length measurement in GFP positive cells. Data are representative of three independent experiments, p<0.001 as determined by one-way ANOVA and post-hoc Bonferroni test. **: p<0.01. E) Immunofluorescent images of representative cells. Red: Tubulin, Green: GFP, Blue: DAPI nucleus. F) Western blot from NSC-34 cells following differentiation and 72 hours treatment with doxycycline. Transfection with Rit-79 but not Rit-FL increased levels of phospho-p38 and SMN in doxycycline-treated cultures.
SMN-dependent exon retention events ranked by percent inclusion.
| Gene Name | Δ-psi | Baye's factor | Event |
|---|---|---|---|
| Cdc123 | 0.82 | 5.40E+273 | chr2:5754702:5755114:-@chr2:5754127:5754159:-@chr2:5743067:5744243:- |
| Nrp2 | 0.72 | 1780.86 | chr1:62832855:62832875:+@chr1:62859108:62859158:+@chr1:62861907:62865269:+ |
| Fam64a | 0.71 | 5.60E+71 | chr11:71856424:71856839:+@chr11:71858483:71858760:+@chr11:71859181:71859595:+ |
| Nubp1 | 0.7 | 10748107.36 | chr16:10419746:10419778:+@chr16:10420349:10420439:+@chr16:10421067:10421530:+ |
| Med7 | 0.67 | 20186.45 | chr11:46250427:46250511:+@chr11:46253308:46253477:+@chr11:46254065:46256223:+ |
| Phb2 | 0.64 | 8.85 | chr6:124665972:124666048:+@chr6:124666443:124666448:+@chr6:124666624:124666967:+ |
| Polh | 0.61 | 1.28422E+34 | chr17:46335583:46335717:-@chr17:46331151:46331365:-@chr17:46327556:46327725:- |
| Mtch2 | 0.61 | 8761.65 | chr2:90689755:90689861:+@chr2:90692973:90693023:+@chr2:90693208:90693270:+ |
| Afg3l1 | 0.6 | 178326.09 | chr8:126022488:126022598:+@chr8:126023892:126024007:+@chr8:126025133:126025333:+ |
| Ptrh2 | 0.6 | 102704.98 | chr11:86497379:86497625:+@chr11:86501538:86501630:+@chr11:86503061:86505959:+ |
| Serinc3 | 0.57 | 2.60E+109 | chr2:163470734:163470889:-@chr2:163464902:163465063:-@chr2:163462543:163462740:- |
| Snrpd3 | 0.57 | 3.80E+74 | chr10:74982059:74982205:+@chr10:74994922:74995114:+@chr10:74998006:75000126:+ |
| Cse1l | 0.57 | 88085852.77 | chr2:166760253:166760389:+@chr2:166761423:166761526:+@chr2:166762842:166762939:+ |
| Dcaf8 | 0.57 | 56.43 | chr1:174078300:174079452:+@chr1:174095979:174096056:+@chr1:174102460:174104214:+ |
| Stxbp1 | 0.56 | 6.29 | chr2:32651536:32651690:-@chr2:32650108:32650233:-@chr2:32643123:32645157:- |
| Kars | 0.55 | 4.9952E+12 | chr8:114535110:114535255:-@chr8:114529532:114529688:-@chr8:114527175:114527340:- |
| Foxk2 | 0.55 | 9140760.75 | chr11:121159822:121160169:+@chr11:121160898:121161107:+@chr11:121168082:121171214:+ |
| Xpnpep3 | 0.55 | 159.21 | chr15:81244862:81244978:+@chr15:81246277:81246424:+@chr15:81257706:81258384:+ |
| Ptp4a2 | 0.54 | 6.67328E+34 | chr4:129522306:129522436:+@chr4:129523709:129523783:+@chr4:129524958:129527231:+ |
| Hnrnph1 | 0.54 | 4.73985E+15 | chr11:50197182:50198238:+@chr11:50198643:50198692:+@chr11:50199279:50200031:+ |
| Fam135a | 0.53 | 370308.6 | chr1:24039502:24039575:-@chr1:24037581:24037735:-@chr1:24035039:24037367:- |
| Neo1 | 0.52 | 494354.79 | chr9:58736208:58736300:-@chr9:58732277:58732435:-@chr9:58728399:58728662:- |
| Pitpnc1 | 0.51 | 692.74 | chr11:107087545:107087608:-@chr11:107077992:107078110:-@chr11:107069205:107073972:- |
| Mprip | 0.5 | 2175532678 | chr11:59585119:59585204:+@chr11:59585654:59585719:+@chr11:59589018:59595260:+ |
| Cct4 | 0.5 | 17774127.29 | chr11:22893267:22893319:+@chr11:22894298:22894387:+@chr11:22895930:22896038:+ |
| Rbms3 | 0.5 | 26954.78 | chr9:116495136:116495213:-@chr9:116491856:116491983:-@chr9:116481864:116487820:- |
| Isca2 | 0.5 | 95.1 | chr12:86114256:86114627:+@chr12:86114743:86114858:+@chr12:86115493:86116043:+ |
| Tarbp2 | 0.5 | 12.89 | chr15:102348601:102349033:+@chr15:102349553:102349722:+@chr15:102351552:102354105:+ |
| Tmem208 | 0.49 | 5.27 | chr8:107852222:107852358:+@chr8:107852508:107852547:+@chr8:107852672:107852957:+ |
| Crls1 | 0.47 | 20.87 | chr2:132675602:132675739:+@chr2:132686945:132687030:+@chr2:132688071:132688139:+ |
| Pank2 | 0.46 | 694.78 | chr2:131099647:131099999:+@chr2:131105893:131106090:+@chr2:131108328:131108504:+ |
| Ndufb5 | 0.45 | 6.40645E+17 | chr3:32645331:32645436:+@chr3:32646519:32646711:+@chr3:32647383:32648279:+ |
| Usp5 | 0.45 | 6.18 | chr6:124767336:124767489:-@chr6:124767002:124767086:-@chr6:124765033:124765677:- |
| Kdm6a | 0.44 | 16.56 | chrX:17851637:17852287:+@chrX:17854502:17854689:+@chrX:17855752:17857062:+ |
| Pstk | 0.43 | 340.94 | chr7:138514615:138514903:+@chr7:138517050:138517344:+@chr7:138517579:138517777:+ |
| Wdfy2 | 0.43 | 5.39 | chr14:63571849:63571979:+@chr14:63573698:63573806:+@chr14:63575117:63580346:+ |
| Sltm | 0.42 | 5 | chr9:70390520:70390888:+@chr9:70391777:70391864:+@chr9:70406844:70410668:+ |
| Nup88 | 0.41 | 9.38 | chr11:70757614:70758240:-@chr11:70757381:70757499:-@chr11:70756560:70756824:- |
| Pxmp3 | 0.4 | 607616.71 | chr3:5563165:5563272:-@chr3:5562669:5562732:-@chr3:5560498:5561764:- |
| Nup85 | 0.4 | 25117.84 | chr11:115439244:115439378:+@chr11:115439478:115439600:+@chr11:115439803:115439934:+ |
| Tyms | 0.4 | 4431.92 | chr5:30398174:30398247:-@chr5:30395006:30395078:-@chr5:30390386:30390726:- |
| Puf60 | 0.4 | 673.05 | chr15:75905972:75906262:-@chr15:75905037:75905087:-@chr15:75902836:75902998:- |
| Shmt2 | 0.4 | 71.44 | chr10:126957974:126958307:-@chr10:126957394:126957473:-@chr10:126957027:126957227:- |
| Prc1 | 0.4 | 11.96 | chr7:87457918:87458017:+@chr7:87458413:87458454:+@chr7:87460000:87461202:+ |
| Gpx8 | 0.39 | 7.37 | chr13:113836380:113836621:-@chr13:113835640:113835901:-@chr13:113832691:113833507:- |
| Ube2v2 | 0.38 | 7109676.49 | chr16:15581152:15581300:-@chr16:15577108:15577233:-@chr16:15551079:15556636:- |
| Uqcrh | 0.38 | 4470.95 | chr4:115747521:115747691:-@chr4:115743273:115743362:-@chr4:115742414:115742629:- |
| Polr3f | 0.38 | 3402.14 | chr2:144361911:144362126:+@chr2:144362902:144363093:+@chr2:144364348:144367731:+ |
| Dnlz | 0.38 | 11.2 | chr2:26207293:26207631:-@chr2:26206855:26206994:-@chr2:26203075:26206078:- |
| Ptpmt1 | 0.38 | 5.68 | chr2:90757586:90757969:-@chr2:90754141:90754332:-@chr2:90748507:90751476:- |
| Crls1 | 0.38 | 5.25 | chr2:132675602:132675739:+@chr2:132680629:132680758:+@chr2:132686945:132687030:+ |
| Ccnb1 | 0.37 | 10.87 | chr13:101555412:101555573:-@chr13:101553420:101553602:-@chr13:101551580:101551738:- |
| Pisd-ps1 | 0.37 | 6.3 | chr11:3025239:3026061:+@chr11:3028932:3029168:+@chr11:3029385:3029523:+ |
| Bzw2 | 0.36 | 1846.79 | chr12:36883255:36883451:-@chr12:36861478:36861542:-@chr12:36856579:36856755:- |
| Fxr1 | 0.36 | 87.52 | chr3:33963025:33963241:+@chr3:33967083:33967174:+@chr3:33967839:33974920:+ |
| Ppp2r2d | 0.36 | 43.83 | chr7:146060093:146060190:+@chr7:146061373:146061538:+@chr7:146062073:146062185:+ |
| Syncrip | 0.35 | 6.92 | chr9:88376894:88377397:-@chr9:88375444:88375603:-@chr9:88374632:88374750:- |
| Tpm3 | 0.34 | 71 | chr3:89891596:89894001:+@chr3:89894935:89895013:+@chr3:89903450:89904824:+ |
| Phf3 | 0.33 | 5.89 | chr1:30919832:30920101:-@chr1:30886688:30888404:-@chr1:30881055:30881364:- |
| Ppp1r12a | 0.32 | 4923.07 | chr10:107688797:107689000:+@chr10:107689813:107689980:+@chr10:107690381:107690551:+ |
| Fundc1 | 0.31 | 557.02 | chrX:17145159:17145234:-@chrX:17135807:17135935:-@chrX:17133690:17135137:- |
| Pcgf5 | 0.31 | 5.94 | chr19:36517334:36517432:+@chr19:36519478:36519567:+@chr19:36530111:36535459:+ |
| Tcp1 | 0.3 | 2.00129E+28 | chr17:13109195:13109495:+@chr17:13110664:13110749:+@chr17:13110909:13113323:+ |
| Ifi27l1 | 0.3 | 10290.22 | chr12:104674773:104674892:+@chr12:104675663:104675734:+@chr12:104675886:104675915:+ |
| Emd | 0.3 | 34.72 | chrX:71501082:71501215:+@chrX:71502217:71502263:+@chrX:71506121:71506935:+ |
| Ddx17 | 0.3 | 29.97 | chr15:79372917:79373016:-@chr15:79371464:79371597:-@chr15:79370839:79370908:- |
| Lypla1 | 0.3 | 12.73 | chr1:4818665:4818730:+@chr1:4820349:4820396:+@chr1:4822392:4822462:+ |
| Ndufs4 | 0.3 | 8.87 | chr13:115178167:115178469:-@chr13:115141656:115141734:-@chr13:115107065:115107237:- |
| Srsf5 | 0.3 | 7.22 | chr12:82047408:82047707:+@chr12:82048298:82048368:+@chr12:82048483:82048782:+ |
| Cops3 | 0.29 | 38.46 | chr11:59646386:59646435:-@chr11:59643649:59643741:-@chr11:59641348:59641527:- |
| Picalm | 0.29 | 9.12 | chr7:97326010:97326113:+@chr7:97330729:97330878:+@chr7:97337660:97337767:+ |
| Serinc3 | 0.28 | 52.88 | chr2:163470734:163470889:-@chr2:163464902:163464924:-@chr2:163462543:163462740:- |
| Mtch2 | 0.27 | 225498.8 | chr2:90689755:90689861:+@chr2:90692997:90693023:+@chr2:90693208:90693270:+ |
| Wbscr22 | 0.26 | 116.88 | chr5:135532712:135532889:-@chr5:135531898:135532254:-@chr5:135529419:135529508:- |
| Ube2j2 | 0.25 | 19.92 | chr4:155329531:155329669:+@chr4:155330477:155330557:+@chr4:155331190:155333713:+ |
| Rai12 | 0.25 | 6.65 | chr11:69784063:69784244:-@chr11:69782995:69783090:-@chr11:69782598:69782698:- |
| Sqle | 0.24 | 12568724541 | chr15:59155362:59155533:+@chr15:59156017:59156112:+@chr15:59157590:59157732:+ |
| Agpat6 | 0.24 | 39.69 | chr8:24301188:24302164:-@chr8:24295001:24295070:-@chr8:24293135:24293435:- |
| Surf4 | 0.24 | 6.16 | chr2:26782289:26782475:-@chr2:26781128:26781204:-@chr2:26780473:26780516:- |
| Mrps18c | 0.23 | 6.72 | chr5:101230927:101231010:+@chr5:101232072:101232129:+@chr5:101232989:101235488:+ |
| Znrf1 | 0.21 | 20.41 | chr8:114059994:114061464:+@chr8:114133193:114133288:+@chr8:114143106:114143211:+ |
| Slc30a9 | 0.21 | 6.2 | chr5:67706917:67707084:+@chr5:67715913:67715972:+@chr5:67718092:67718191:+ |
| Pot1a | 0.2 | 149.81 | chr6:25755875:25755941:-@chr6:25750284:25750510:-@chr6:25740138:25744674:- |
SMN-dependent intron skipping events ranked by percent inclusion.
| Gene Name | Δ-psi | Baye's factor | Event |
|---|---|---|---|
| 2500003M10Rik | 0.41 | 227.54 | chr3:90311467:90311548:-@chr3:90310030:90311180:- |
| Rpl7 | 0.26 | 317494357.1 | chr1:16093684:16093765:-@chr1:16093591:16093650:- |
| Fasn | 0.16 | 44.04 | chr11:120671337:120671363:-@chr11:120671118:120671268:- |
| Nap1l1 | 0.11 | 7.64 | chr10:110933096:110933161:+@chr10:110933810:110933939:+ |
| Ptma | 0.06 | 1.38696E+14 | chr1:88426540:88426688:+@chr1:88426804:88426811:+ |